Navidea Biopharmaceuticals Inc. cut its losses in half in 2016 compared with the prior year. Revenue increased by 66 percent to a record $22 million but won't compare to this year's results because it's an entirely different company.
The Dublin biotech company announced after markets closed Wednesday that it lost $14.3 million, driven by whopping interest expenses of $14.9 million, double that of the previous year.
Navidea is now debt-free and "has sufficient cash to advance all of our existing…
Navidea Biopharmaceuticals Inc. cut its losses in half in 2016 compared with the prior year. Revenue increased by 66 percent to a record $22 million but won't compare to this year's results because it's an entirely different company.
The Dublin biotech company announced after markets closed Wednesday that it lost $14.3 million, driven by whopping interest expenses of $14.9 million, double that of the previous year.
Navidea is now debt-free and "has sufficient cash to advance all of our existing…